Evidence mapPaperPMID 42516951Full record

ArticleFrontiers in cardiovascular medicine2026

Precision cardiovascular medicine: global imperative for equity through innovation.

Jose R Medina-Inojosa, Fatima Rodriguez, Francisco Lopez-Jimenez, Laurence S Sperling

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jose R Medina-InojosaDivision of Cardiology, Emory Clinical Cardiovascular Research Institute, Atlanta, GA, United States.
Fatima RodriguezDivision of Cardiovascular Medicine, The Cardiovascular Institute, Stanford, CA, United States.
Francisco Lopez-JimenezDivision of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, United States.
Laurence S SperlingDivision of Cardiology, Emory Clinical Cardiovascular Research Institute, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease remains the world's leading cause of death, with a disproportionate burden falling on low- and middle-income countries. Emerging precision medicine approaches, such as artificial intelligence, multiomics, and digital diagnostics, offer transformational potential for prevention and management. Yet, without equity-centered policies, these innovations risk amplifying disparities. The World Heart Federation (WHF) proposes a framework premised on innovation as a public good and equity as a universal right. Through the World Heart Observatory, Digital Health Roadmap, and Emerging Leaders Program, the WHF operationalizes equity across governance, workforce, and care delivery. Drawing on exemplars from Africa, Latin America, and South/Southeast Asia, we outline implementation strategies and policy levers to translate science into population-level impact. Precision cardiovascular medicine can become the standard for all-but only when designed with equity from inception.

Indexed as

artificial intelligencecardiovascular diseasedigital healthhealth equityimplementation sciencelow- and middle-income countriesprecision medicineWorld Heart Federation

Identifiers

PMID42516951
PMCPMC13402399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.